REGN vs RVMD
Regeneron Pharmaceuticals and Revolution Medicines, Inc., both Healthcare
Regeneron Pharmaceuticals is the larger company at $64B against $35B. Over the past year RVMD returned +517% against +48% for REGN. Ryufin's sector-relative Smart Score puts RVMD ahead, 10/10 against 9/10.
| Figure | REGN | RVMD |
|---|---|---|
| Last close | $815 | $216 |
| Market cap | $64B | $35B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 20.1 | n/a |
| 1-year return | +48% | +517% |
| 5-year return | +43% | +635% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 10/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Regeneron Pharmaceuticals
Revenue of $4.3B in Q2 2026, net income $1.3B. Its largest reported line is Share Of Profit Losses, 50% of the disclosed total.
Revolution Medicines, Inc.
Open these two in the interactive comparison to add more names, change the period or read the correlation.